Target- |
MechanismAngiogenesis inhibitors [+1] |
Active Org.- |
|
Active Indication- |
|
Drug Highest PhaseDiscontinued |
First Approval Ctry. / Loc.- |
First Approval Date- |
A Phase III Randomized Placebo Controlled and Double Blinded Study of IM862 for Patients With Muco-Cutaneous AIDS Associated Kaposi's Sarcoma
The purpose of this study is to see if it is safe and effective to use IM862 to treat Kaposi's sarcoma (KS) in AIDS patients.
A Phase II Trial Of IM862 Combined With Paclitaxel And Carboplatin In Newly Diagnosed Advanced Epithelial Ovarian Or Primary Peritoneal Carcinoma Followed By IM862 Consolidation Therapy
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. IM-862 may kill tumor cells by stopping blood flow to the tumor and by stimulating a person's white blood cells to kill tumor cells. Combining chemotherapy and IM-862 may kill more tumor cells.
PURPOSE: Randomized phase II trial to study the effectiveness of combination chemotherapy and IM-862 in treating patients who have resected stage III ovarian cancer or primary peritoneal cancer.
100 Clinical Results associated with Cytran, Inc.
0 Patents (Medical) associated with Cytran, Inc.
100 Deals associated with Cytran, Inc.
100 Translational Medicine associated with Cytran, Inc.